Payer Power: What Are The Future Implications For Life Science Companies Developing New Products?
How US Commercial Payers Will Manage Rapidly Increasing Drug Costs
Executive Summary
Payers cannot control the pricing of new products by biopharmaceutical companies, but their goal is to deliver quality health care in a cost-effective manner. Several payer medical directors representing over 100 million commercially insured members have shared their insights for managing the challenging US market – revealing their thoughts on drug pricing currently, and steps they plan to take in the next 3 to 5 years to better control rising costs.
You may also be interested in...
Sartans Recalled In UK As Further Impurity Is Confirmed
Certain batches of two angiotensin II receptor blockers, or sartans, are being recalled in the UK after an impurity that can potentially increase the risk of cancer over time was detected.
UK Regulator Eyes Expedited Process For Securing Full ICH Membership
The UK is on a mission to re-join the International Council for Harmonisation as a fully active member with voting rights.
Advanz Partners With Eisai For Zonisamide
Advanz has entered into an agreement with Eisai to acquire rights to its Zonegran zonisamide brand in Europe, the Middle East, Russia and Australia. Advanz said the move was “in keeping with our strategic growth plans” after the company was recently acquired by Nordic Capital in an $846m deal.